Mohammed Milhem

53.3k citations
227 papers · 7.0k · 5 hit papers · h-index 38

Impact in

  • Oncology top 0.5%
    • CAR-T cell therapy research
    • Cancer Immunotherapy and Biomarkers
    • Vascular Tumors and Angiosarcomas
    • Cutaneous Melanoma Detection and Management
  • Immunology top 2%
    • Immunotherapy and Immune Responses

Papers in

    • CAR-T cell therapy research 52
    • Cancer Immunotherapy and Biomarkers 50
    • Cutaneous Melanoma Detection and Management 18
    • Melanoma and MAPK Pathways 26

Mohammed Milhem

220 papers receiving 6.9k citations

Mohammed Milhem's Hit Papers

Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials 2018 · 509 citations
5090+4+9Years since publication2505007501000

Peers

Mohammed Milhem
Comparison fields: 5 of 126
  • Oncology 3.5k
  • Immunology 1.4k
  • Pulmonary and Respiratory Medicine 1.7k
  • Genetics 930
  • Molecular Biology 2.2k
Replace Ravi A. Madan with:
Ravi A. Madan United States
Pieter Demetter Belgium
Masaki Mandai Japan
Michel Obéid Switzerland
Richard Lake Australia
Matthew L. Sherman United States
Isabelle Cremer France
Harry Hollema Netherlands
Shashikant Lele United States
Tullia C. Bruno United States
Mohammed Milhem relative to Ravi A. Madan United States Ravi A. Madan's profile →
Citations per field
00.5×2.8×
Ravi A. Madan · 1×
Citations per year

Countries citing papers authored by Mohammed Milhem

Since Specialization
Citations

This map shows the geographic impact of Mohammed Milhem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed Milhem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed Milhem more than expected).

Fields of papers citing papers by Mohammed Milhem

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed Milhem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed Milhem. The network helps show where Mohammed Milhem may publish in the future.

Co-authors

The 25 scholars most cited alongside Mohammed Milhem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mohammed Milhem Line = papers co-authored together Mohammed Milhem links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 227 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
Hit paper breakdown →
20121071
2
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial
Hit paper breakdown →
2015585
3
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Hit paper breakdown →
2018509
4
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
Hit paper breakdown →
2017482
5
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
Hit paper breakdown →
2016443
6 2016245
7 2004165
8 2014105
9 201697
10 200681
11 202080
12 201677
13 202171
14 201469
15 201768
16 201168
17 201665
18 202363
19 201559
20 201856

About Mohammed Milhem

Mohammed Milhem is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology and Genetics, having authored 227 papers that have together received 7.0k indexed citations. Recurring topics across this work include CAR-T cell therapy research (52 papers), Cancer Immunotherapy and Biomarkers (50 papers), Sarcoma Diagnosis and Treatment (42 papers), Immunotherapy and Immune Responses (35 papers), Melanoma and MAPK Pathways (26 papers), Virus-based gene therapy research (25 papers), Cutaneous Melanoma Detection and Management (18 papers) and Cancer Research and Treatments (15 papers). The work is most often cited by research in Oncology (3.5k citations), Immunology (1.4k citations), Pulmonary and Respiratory Medicine (1.7k citations), Genetics (930 citations) and Molecular Biology (2.2k citations). Mohammed Milhem has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Igor Puzanov, Howard L. Kaufman, Claus Garbe, Brian Andrew Van Tine, Lisa Chen, Robert H.I. Andtbacka, Omid Hamid, Yousef Zakharia, Varun Monga and Dirk Schadendorf. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Cancers and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact